FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280495737> ?p ?o ?g. }

• W4280495737 endingPage "e2212327" @default.
• W4280495737 startingPage "e2212327" @default.
• W4280495737 abstract "<h3>Importance</h3> Adjuvant drugs are used to reduce the risk of tumor recurrence in patients with cancer who are successfully treated with first-line therapy. The same drugs used in the metastatic or first-line setting are often used in the adjuvant setting, and although the resulting adverse effects may be similar between the 2 settings, tolerability may be different. <h3>Objective</h3> To compare the discontinuation rates of drugs in the adjuvant setting and in the metastatic setting in clinical trials of cancer drugs. <h3>Design, Setting, and Participants</h3> This cross-sectional study examined clinical trials of cancer drugs with results published in major medical and oncology journals between July 2018 through June 2021. Because adjuvant drugs can be used in a metastatic setting, included trials were conducted in an adjuvant setting. Data were analyzed December 2021. <h3>Exposures</h3> Drugs used in the adjuvant setting, which were also used in the metastatic setting for the same tumor indication. <h3>Main Outcomes and Measures</h3> Discontinuation rates in the adjuvant and metastatic settings, which were calculated by dividing the total number of study participants who withdrew or discontinued because of adverse events by the number of participants allocated to the drug arm. <h3>Results</h3> A total of 29 trials with a drug being used in the adjuvant and metastatic setting were found. In the adjuvant setting, the median (IQR) age for study participants was 58.0 (52.0-63.5) years, and the median (IQR) percentage of male participants was 55.5% (0.9%-64.8%). In the metastatic setting, the median (IQR) age for study participants was 61 years, and the median (IQR) percentage of male participants was 55.2% (2.0%-66.0%). Overall, a median (IQR) 21.4% (17.7%-29.4%) of participants discontinued because of adverse events or patient withdrawal in the adjuvant setting compared with a median (IQR) 15.9% (9.7%-21.3%) in the metastatic setting (<i>P</i> = .01). Checkpoint inhibitors (median [IQR] rate of discontinuation, 21.4% [18.6%-31.3%] vs 15.2% [9.9%-19.5%];<i>P</i> = .01) and targeted drugs (median [IQR] rate of discontinuation, 27.7% vs 14.0%;<i>P</i> < .001) demonstrated a higher rate of discontinuation in the adjuvant setting while cytotoxic drugs (median [IQR] rate of discontinuation, 16.6% [12.2%-23.3%] vs 25.5% [19.8%-28.8%];<i>P</i> = .07) showed no difference between the 2 settings. The largest differences between adjuvant and metastatic discontinuation rates were for sorafenib (renal cell carcinoma, 43.8% vs 5.5%; difference, 38.2%), imatinib (gastrointestinal stromal tumor, 37.4% vs 6.1%; difference, 31.2%), and erlotinib (non–small cell lung cancer, 37.5% vs 8.4%; difference, 29.0%). <h3>Conclusions and Relevance</h3> In this cross-sectional study of clinical trials that involved novel cancer drugs, drugs used in the adjuvant setting were associated with significantly higher discontinuation rates than in the metastatic setting. This finding suggests that the proposed benefits of adjuvant therapy need to be taken in context of patient’s drug tolerance." @default.
• W4280495737 created "2022-05-22" @default.
• W4280495737 creator A5007770903 @default.
• W4280495737 creator A5052994844 @default.
• W4280495737 creator A5079876604 @default.
• W4280495737 creator A5084173972 @default.
• W4280495737 date "2022-05-16" @default.
• W4280495737 modified "2023-09-26" @default.
• W4280495737 title "Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials" @default.
• W4280495737 cites W2033498751 @default.
• W4280495737 cites W2134644638 @default.
• W4280495737 cites W2150955627 @default.
• W4280495737 cites W2167663287 @default.
• W4280495737 cites W2616160160 @default.
• W4280495737 cites W2746717271 @default.
• W4280495737 cites W2763004155 @default.
• W4280495737 cites W2769165694 @default.
• W4280495737 cites W2899127460 @default.
• W4280495737 cites W2912353875 @default.
• W4280495737 cites W2914335201 @default.
• W4280495737 cites W2945679037 @default.
• W4280495737 cites W2997351648 @default.
• W4280495737 cites W3015200517 @default.
• W4280495737 cites W3103479524 @default.
• W4280495737 cites W3137208756 @default.
• W4280495737 cites W3153228158 @default.
• W4280495737 cites W4210477674 @default.
• W4280495737 doi "https://doi.org/10.1001/jamanetworkopen.2022.12327" @default.
• W4280495737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35576006" @default.
• W4280495737 hasPublicationYear "2022" @default.
• W4280495737 type Work @default.
• W4280495737 citedByCount "4" @default.
• W4280495737 countsByYear W42804957372022 @default.
• W4280495737 countsByYear W42804957372023 @default.
• W4280495737 crossrefType "journal-article" @default.
• W4280495737 hasAuthorship W4280495737A5007770903 @default.
• W4280495737 hasAuthorship W4280495737A5052994844 @default.
• W4280495737 hasAuthorship W4280495737A5079876604 @default.
• W4280495737 hasAuthorship W4280495737A5084173972 @default.
• W4280495737 hasBestOaLocation W42804957371 @default.
• W4280495737 hasConcept C121608353 @default.
• W4280495737 hasConcept C126322002 @default.
• W4280495737 hasConcept C143998085 @default.
• W4280495737 hasConcept C197934379 @default.
• W4280495737 hasConcept C2777863537 @default.
• W4280495737 hasConcept C2777982462 @default.
• W4280495737 hasConcept C2778375690 @default.
• W4280495737 hasConcept C2778715236 @default.
• W4280495737 hasConcept C535046627 @default.
• W4280495737 hasConcept C71924100 @default.
• W4280495737 hasConceptScore W4280495737C121608353 @default.
• W4280495737 hasConceptScore W4280495737C126322002 @default.
• W4280495737 hasConceptScore W4280495737C143998085 @default.
• W4280495737 hasConceptScore W4280495737C197934379 @default.
• W4280495737 hasConceptScore W4280495737C2777863537 @default.
• W4280495737 hasConceptScore W4280495737C2777982462 @default.
• W4280495737 hasConceptScore W4280495737C2778375690 @default.
• W4280495737 hasConceptScore W4280495737C2778715236 @default.
• W4280495737 hasConceptScore W4280495737C535046627 @default.
• W4280495737 hasConceptScore W4280495737C71924100 @default.
• W4280495737 hasIssue "5" @default.
• W4280495737 hasLocation W42804957371 @default.
• W4280495737 hasLocation W42804957372 @default.
• W4280495737 hasLocation W42804957373 @default.
• W4280495737 hasLocation W42804957374 @default.
• W4280495737 hasOpenAccess W4280495737 @default.
• W4280495737 hasPrimaryLocation W42804957371 @default.
• W4280495737 hasRelatedWork W1490515507 @default.
• W4280495737 hasRelatedWork W2009822178 @default.
• W4280495737 hasRelatedWork W2059313976 @default.
• W4280495737 hasRelatedWork W2089245388 @default.
• W4280495737 hasRelatedWork W2896659597 @default.
• W4280495737 hasRelatedWork W2996750011 @default.
• W4280495737 hasRelatedWork W4200628345 @default.
• W4280495737 hasRelatedWork W4283394029 @default.
• W4280495737 hasRelatedWork W4320710015 @default.
• W4280495737 hasRelatedWork W2183331092 @default.
• W4280495737 hasVolume "5" @default.
• W4280495737 isParatext "false" @default.
• W4280495737 isRetracted "false" @default.
• W4280495737 workType "article" @default.